Billionaire investors buy shares in Hims & Hers Health, a growing telehealth company with $13.3M Q2 net income.

Billionaire investors are increasingly buying shares in Hims & Hers Health, a subscription-based telehealth company providing prescriptions for various treatments. The subscriber base grew 43% to 1.9 million, and the introduction of compounded semaglutide contributed to a Q2 net income of $13.3 million. Despite potential competition from insurers and the risk of declining semaglutide sales, the company's profitability and growth make it appealing for high-risk investors.

September 01, 2024
3 Articles

Further Reading